The most lucrative race in the pharmaceutical industry is entering a new and more crowded phase. After years in which Novo Nordisk and Eli Lilly built a near-duopoly over the blockbuster class of weight-loss drugs known as GLP-1s, a wave of challengers led by Pfizer and Amgen is betting it can finally crack a market projected to reach $100 billion by 2030. The next chapter will be defined not by a single breakthrough but by an expanding menu of options, including convenient pills, longer-lasting injections, and drugs designed to preserve muscle, as drugmakers scramble to find the angle that wins them a piece of the prize, according to reporting from CNBC.
For investors, the stakes are enormous. The obesity drug category has already reshaped the fortunes of Novo Nordisk and Eli Lilly, sending their valuations soaring and turning weight-loss treatments into one of the defining growth stories in healthcare. The question now is whether the incumbents can defend their lead or whether deep-pocketed rivals can carve out enough share to justify the billions they are pouring into research.
The Incumbents Set a High Bar
Novo Nordisk and Eli Lilly did not just create this market, they continue to push it forward. The current phase opened with a milestone that had eluded the industry for years: effective GLP-1 medicines in pill form rather than injections. Novo Nordisk led the way with an oral version of its blockbuster therapy, and Eli Lilly’s own oral approval is expected within months. Pills matter enormously because they remove the biggest barriers to adoption, the needle and the cold-chain logistics that injections require, opening the treatment to far more patients and far larger markets.
Both companies are racing to extend their dominance across an entire spectrum of formats. Executives across the industry expect the coming years to bring an expanding range of treatments tailored to individual needs, from daily pills and less-frequent injections to combination regimens and drugs engineered to preserve lean muscle mass while patients shed fat. That last category addresses one of the most persistent criticisms of current GLP-1 therapies, which can cause patients to lose muscle along with fat. The incumbents are determined to define the next standard before challengers can.
Pfizer Rebuilds Through Acquisition
Few companies have more to prove in this arena than Pfizer. The pharmaceutical giant stumbled badly in its initial push into obesity, halting development of two of its own GLP-1 pills over safety concerns and watching rivals pull further ahead. Rather than retreat, Pfizer chose to buy its way back into contention, acquiring the obesity biotech Metsera and with it a deeper pipeline of GLP-1 and next-generation candidates.
The centerpiece of that acquisition is an ultra-long-acting injectable GLP-1 receptor agonist. Pfizer has reported positive mid-stage trial data in adults with obesity or overweight who do not have type 2 diabetes, and the company has said it expects to advance a slate of late-stage trials with the drug in 2026. The strategic appeal is convenience: the drug showed potential to be administered monthly rather than weekly, a meaningful improvement for patients weary of frequent injections. If Pfizer can deliver comparable weight loss with a fraction of the dosing burden, it could turn a late start into a genuine competitive edge.
Amgen Bets on Less-Frequent Dosing
Amgen is pursuing a similar thesis with its candidate MariTide, a differentiated antibody-peptide conjugate that activates the GLP-1 receptor while blocking a second receptor involved in metabolism. The defining feature is dosing frequency. MariTide is designed for monthly or even less-frequent administration, and Amgen has launched an ambitious program of six global late-stage studies spanning chronic weight management, cardiovascular outcomes, heart failure, and obstructive sleep apnea.
One study is specifically testing whether patients on weekly therapies from Novo Nordisk or Eli Lilly can switch to MariTide on an every-eight-week or quarterly schedule. That design is a direct challenge to the incumbents, aimed at convincing patients and physicians that an existing regimen can be traded for something far more convenient without sacrificing results. By targeting multiple related conditions at once, Amgen is also positioning MariTide as more than a weight-loss drug, broadening its potential market and its appeal to insurers.
The Smaller Challengers and the Convenience Wars
The competition extends well beyond the largest names. Structure Therapeutics is developing an oral GLP-1 drug called aleniglipron, with mid-stage results showing that adults on the two highest doses lost roughly 16 percent more body weight than those on placebo after 44 weeks, a result that puts a smaller player firmly in the conversation. Other firms are pushing the convenience frontier even further, with some testing drugs that could be administered monthly or potentially even quarterly.
That arms race over dosing convenience captures the strategic logic of the entire next wave. The first generation of GLP-1 drugs proved that the science works and that demand is nearly insatiable. The next generation will compete on the dimensions that determine real-world adoption: whether a treatment comes as a pill or a shot, how often a patient must take it, how well it preserves muscle, and how many related conditions it can address. Each of those attributes represents a lever a challenger can pull to peel away share from the leaders.
Beyond Weight Loss: A Widening Set of Uses
Part of what makes the next wave so commercially significant is that the science is spilling well beyond weight management itself. Drugmakers increasingly see GLP-1 medicines as platforms with potential across a range of related conditions, including cardiovascular disease, heart failure, sleep apnea, and metabolic disorders tied to obesity. Amgen’s decision to test MariTide across four distinct disease areas at once reflects that ambition, and it changes the competitive math. A drug that can demonstrate benefits beyond the scale, particularly in reducing cardiovascular risk, becomes far easier to justify to insurers and far stickier with patients who have multiple health concerns.
That broadening also reshapes how analysts size the opportunity. The $100 billion figure often cited for 2030 may understate the long-term potential if these therapies become standard treatment for conditions that today are managed with entirely different drug classes. For challengers trying to break the duopoly, proving a differentiated benefit in one of these adjacent indications could be the wedge that establishes a foothold, even against rivals with a head start in pure weight loss.
What It Means for Investors
The obesity drug boom has been one of the most powerful themes in the market, and the intensifying competition cuts in two directions. A larger field of effective treatments should expand the overall market, improve patient access, and accelerate the shift toward the convenient formats that drive mass adoption, a tailwind for the category as a whole. At the same time, more competitors mean pricing pressure and the risk that today’s dominant players see their extraordinary margins eroded as alternatives proliferate.
For the incumbents, the challenge is to keep innovating fast enough to stay ahead of well-funded rivals who have shown they will spend aggressively, including through acquisitions, to get into the game. For the challengers, the task is to prove their drugs are not merely comparable but meaningfully better on convenience, tolerability, or breadth of benefit. The healthcare sector has become a focal point for growth investors much the way the technology sector has, a dynamic visible across the market’s appetite for the best stocks positioned for the years ahead and in the way capital continues chasing the largest secular themes, from artificial intelligence to weight loss, as covered in analysis of how big technology spending is being rewarded by the market.
The obesity market’s trajectory toward $100 billion by 2030 ensures that the competition will only intensify. The companies that emerge as long-term winners will be those that read the next phase correctly, recognizing that the battle has shifted from proving the science to delivering it in the form patients actually want.
